[Skip to Content]

NICE rapid review of previous technology appraisal – intravitreal ranibizumab with DMO

Mar 07

College Statement The National Institute of Clinical Excellence (NICE) has completed a rapid review of the previous technology appraisal of the use of intravitreal ranibizumab in patients with diabetic macular oedema. The new guidance document on ranibizumab for diabetic macular oedema, (TA274), published on 27 February 2013, recommends that patients with DMO can be commenced

  • 7 March 2013

Updated guidance on Emergency Eye Care

Mar 05

An eye condition is an emergency if its occurrence is unpredictable and it requires treatment or admission at short notice to avoid damage to the eye or eyesight. The College will not attempt to identify every type of case that falls into the emergency category: it is the responsibility of the consultant under whose care

  • 5 March 2013

Alessi praises new guide to commissioning high value eye care

Feb 14

Dr Charles Alessi has welcomed new guidance for commissioners of eye care from the College of Optometrists and the Royal College of Ophthalmologists. Written by leading eye care clinicians with support from experienced clinical commissioners at the National Association of Primary Care, Royal College of General Practitioners and the Department of Health’s Right Care Team, it will provide valuable

  • 14 February 2013

Eye health professionals raise alarm over reports of growing number of patients denied cataract surgery

Jan 16

Royal College of Ophthalmologists, College of Optometrists, OpticalConfederation and Local Optical Committee Support Unit issue joint statement London, 13 August 2012 The Royal College of Ophthalmologists has expressed its concern over reports that patients in more than half of PCTs in England are being denied cataract surgery unless their ability to read the optometrists’ test

  • 16 January 2013

IOL VIP Revolution lens implants report in the Daily Telegraph

Jan 15

On 7 January 2013, there was a report in the Daily Telegraph by their medical editor, Rebecca Smith on IOL VIP Revolution lens implant for patients with central visual loss due to macular degeneration, particular the dry type. (http://www.telegraph.co.uk/health/healthnews/9785591/Eye-implant-hope-for-common-cause-of-blindness.html) The report said the procedure costs £11,000 and is only available at the private London Eye

  • 15 January 2013